-
Product Insights
NewNarcolepsy – Drugs In Development, 2024
Empower your strategies with our Narcolepsy – Drugs In Development, 2024 report and make more profitable business decisions. Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations, and sleep paralysis. Narcolepsy treatment includes lifestyle changes, medication, and counseling. The Narcolepsy drugs in development market research report provide comprehensive information on the therapeutics under development for Narcolepsy, complete with analysis by stage of development, drug target, mechanism...
-
Product Insights
NewBatten Disease – Drugs In Development, 2024
Empower your strategies with our Batten Disease – Drugs In Development, 2024 report and make more profitable business decisions. Batten disease, a rare genetic disorder, belongs to a group of progressive degenerative neurometabolic disorders known as the neuronal ceroid lipofuscinoses. Symptoms of Batten disease usually become apparent between five and 15 years of age. Symptoms include vision loss, lack of muscle coordination, mental retardation or decreasing mental function, emotional disturbances, seizures, muscle spasms, deterioration of muscle tone, and movement problems. The...
-
Product Insights
NewEncephalopathy – Drugs In Development, 2024
Empower your strategies with our Encephalopathy – Drugs In Development, 2024 report and make more profitable business decisions. Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Symptoms include seizures, difficulty speaking or swallowing, trembling, involuntary twitching, and muscle weakness. Causes include traumas or injuries, genetics, liver disease, hypoxic condition, Lyme disease, and organ failure. The Encephalopathy drugs in development market research report provide comprehensive information on the therapeutics under development for Encephalopathy,...
-
Product Insights
NewGeneralized Anxiety Disorder (GAD) – Drugs In Development, 2024
Empower your strategies with our Generalized Anxiety Disorder (GAD) – Drugs In Development, 2024 report and make more profitable business decisions. Generalized anxiety disorder is a mental health disorder that produces fear, worry, and a constant feeling of being overwhelmed. It is characterized by excessive, persistent, and unrealistic worry about everyday things. Individuals with GAD typically experience heightened anxiety and apprehension, anticipating negative outcomes in everyday situations. Physical symptoms may include restlessness, muscle tension, fatigue, and difficulty concentrating. Unlike specific phobias...
-
Product Insights
NewIntracerebral Hemorrhage – Drugs In Development, 2024
Empower your strategies with our Intracerebral Hemorrhage – Drugs In Development, 2024 report and make more profitable business decisions. Intracerebral hemorrhage (ICH), a devastating stroke subtype, involves the formation of a hematoma within the brain parenchyma, with or without extension into the ventricles. Accounting for 10-15% of all strokes, non-traumatic ICH is linked to high morbidity and mortality. Risk factors encompass chronic hypertension, amyloid angiopathy, anticoagulation, and vascular malformations. The resulting brain injury is categorized as primary, signifying initial damage by...
-
Product Insights
NewLeukodystrophies – Drugs In Development, 2024
Empower your strategies with our Leukodystrophies – Drugs In Development, 2024 report and make more profitable business decisions. Leukodystrophies, a collection of rare genetic disorders impacting the central nervous system (CNS), specifically the brain and spinal cord, cause damage to the CNS's white matter. This damage hampers or obstructs signals between nerve cells, resulting in varied symptoms such as movement difficulties, vision and hearing impairment, and cognitive challenges. Due to the multitude of leukodystrophy types with differing symptoms, diagnosis poses a...
-
Product Insights
NewPostherpetic Neuralgia – Drugs In Development, 2024
Empower your strategies with our Postherpetic Neuralgia – Drugs In Development, 2024 report and make more profitable business decisions. Postherpetic neuralgia (PHN) emerges as the predominant long-term consequence of varicella-zoster virus (VZV) reactivation, commonly known as herpes zoster or shingles. VZV, responsible for childhood varicella (chickenpox), historically affected the majority of American adults before widespread vaccination. While future generations may experience lower rates of herpes zoster and PHN, the latter remains clinically significant. PHN diagnosis heavily relies on history and physical...
-
Product Insights
NewTremor – Drugs In Development, 2024
Empower your strategies with our Tremor – Drugs In Development, 2024 report and make more profitable business decisions. Tremor is a neurological condition characterized by involuntary shaking or trembling movements in various body parts, primarily the hands but potentially affecting the arms, legs, head, vocal cords, and trunk, as a result of uncontrollable muscle contractions. Its impact varies, causing intermittent or constant challenges in daily tasks like writing, typing, eating, and dressing. While not life-threatening, severe cases can lead to disabilities....
-
Product Insights
NewEpileptic Encephalopathy – Drugs In Development, 2024
Empower your strategies with our Epileptic Encephalopathy – Drugs In Development, 2024 report and make more profitable business decisions. Epileptic encephalopathies, characterized by epileptiform abnormalities and progressive cerebral dysfunction, present in eight age-related syndromes as per the International League Against Epilepsy. Neonatal syndromes include early myoclonic encephalopathy and Ohtahara syndrome, while infancy sees West syndrome and Dravet syndrome. Childhood and adolescence encompass myoclonic status, Lennox-Gastaut syndrome, Landau-Kleffner syndrome, and epilepsy with continuous spike waves during slow wave sleep. Diagnosis entails EEG...
-
Product Insights
NewPartial Seizure – Drugs In Development, 2024
Empower your strategies with our Partial Seizure – Drugs In Development, 2024 report and make more profitable business decisions. Focal onset seizures, or partial seizures, are prevalent neurological disorders marked by abnormal electrical activity in specific brain regions. Manifesting in diverse forms, symptoms range from subtle sensory disruptions to noticeable motor movements and altered consciousness. Precise diagnosis relies on clinical evaluation, neuroimaging, and electroencephalography. Managing focal onset seizures involves a range of strategies, including antiepileptic medications, surgical interventions, and lifestyle adjustments....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.